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The pharmacokinetic (PK) proﬁle of nicotine delivered by an Electronic Vapour Product (EVP) was
characterised in a 2-part study in smokers. The study was designed as a randomised, controlled, four-way
crossover trial. Part 1 compared an unﬂavoured e-liquid (UF2.0%) and a ﬂavoured e-liquid (FL2.0%) to a
conventional cigarette (CC; JPS Silver King Size, 0.6 mg) and a licensed nicotine inhalator (Nicorette®;
15 mg). Part 2 compared e-liquids with increasing nicotine concentrations (0%, 0.4%, 0.9%, 2.0%). Subjects
used each different product for a daily use session. In Part 1, maximum plasma nicotine concentration
(Cmax) for UF2.0%, FL2.0%, Nicorette® and CC was 3.6, 2.5, 2.5 and 21.2 ng/mL, respectively. The time to
maximum plasma nicotine concentration (Tmax) was longer for the EVP (UF2.0%, 9.0 min; FL2.0%,
10.0 min) and the nicotine inhalator (13.0 min) compared to CC (3.0 min). In Part 2, EVP with 0%, 0.4%,
0.9% and 2.0% nicotine produced Cmax values of 0.6, 1.0, 1.9 and 3.6 ng/mL, respectively. At the maximum
nicotine concentration of 2% as prescribed by the European Tobacco Directive, the EVP achieved nicotine
delivery that was comparable to the inhalator. EVPs thus offer a potential alternative to nicotine inhalator
devices for those ﬁnding it difﬁcult to quit smoking.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
There has been rapid growth in the use of electronic cigarette (e-
cigarettes) otherwise known as electronic vapour products (EVPs)
among smokers worldwide (Adkison et al., 2013; Berg et al., 2014;
Dockrell et al., 2013; King et al., 2013). Nicotine Replacement
Therapy (NRT) has had modest success in helping smokers to quit
(Beard et al., 2015) and studies have shown EVPs are often used as a
means to stop smoking conventional cigarettes (CC) (Berg et al.,
2014; Dockrell et al., 2013; Etter and Bullen, 2011).
EVPs comprise of three principal components: a battery for
power supply; an e-liquid reservoir and a heating element, or
atomiser. When a user draws on the device, the e-liquid in close
proximity to the heater rapidly vaporises and condenses into anarbon monoxide; EVP, elec-
rapy.
(T. Walele).
r Inc. This is an open access articleaerosol. Typically e-liquids consist of propylene glycol, glycerol,
water, ﬂavouring and/or nicotine. EVPs exist in various designs, and
may vary considerably in the amount of nicotine they deliver in the
aerosol. The use of new-generation EVPs, (i.e. systems with large-
capacity batteries and larger atomisers/“Mods”) has been shown
to be more effective in increasing blood nicotine levels in users,
compared with ﬁrst generation devices (i.e. devices with low-
capacity batteries, designed to look like CC) (Farsalinos et al.,
2014b). The nicotine concentration in the e-liquid also appeared
to correlate with nicotine uptake levels achieved by users (Etter,
2014). Furthermore, recent studies have shown that experienced
users of EVPs were able to achieve higher levels of blood nicotine
when compared to novice users and that blood nicotine levels are
similar to those of CC smokers, (i.e. around 15 ng/mL), particularly if
they use the product ad-libitum (Dawkins and Corcoran, 2013; IOM,
2011; Vansickel and Eissenberg, 2013). When experienced EVP
users used their preferred EVP product, with nicotine concentra-
tions in e-liquids ranging from 12 to 24 mg/mL (1.2e2.4% w/v),
plasma nicotine rose to a mean of 19.2 ng/mL immediately after useunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Schematic of the external appearance and parts of the tested EVP. From left to
right, pieces are: the housing, which contains the battery and has a LED indicator on
the side, the atomiser, the capsule containing the e-liquid and the mouthpiece.
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differences in pufﬁng topography, with experienced users taking
longer and larger puffs (up to 4 s and up to 101mL) than novice EVP
users and CC smokers (around 2 s, 51 mL) (Farsalinos et al., 2013b;
Spindle et al., 2015).
Despite a number of pharmacokinetic (PK) studies performed,
being able to draw any ﬁrm conclusions on the capacity of EVPs to
deliver nicotine has proven to be challenging. This is in part due to
the lack of standardised methodologies for the comparative testing
of EVPs (Orr, 2014). In the UK, the Medicines and Healthcare
Products Regulatory Agency (MHRA) has strongly encouraged
manufacturers to register EVPs as medicinal products (MHRA,
2013). According to the Agency, such regulation would ensure
that products comply with quality standards. The Royal College of
Physicians was supportive of such regulation, and also requested
that ‘clear, simple and easily achievable standards of dose kinetics and
purity are established to encourage new innovation in nicotine prod-
ucts and new entrance into the nicotine market’. At the European
level, under the revised Directive on Tobacco Product a maximum
concentration of 20 mg/mL (2% w/v) as a limit for nicotine will be
set for e-liquids placed on the market after May 2016. After that
time no products can be placed on the market above that limit,
except for those regulated as medicinal products (EU, 2014).
Here, we report the results of a human PK study, consisting of
two parts. The aim of Part 1 was to compare the plasma nicotine PK
proﬁle of an unﬂavoured (UF) and a ﬂavoured (FL) e-liquid con-
taining 2.0% nicotine delivered via the EVP closed-system prototype
device to the plasma PK proﬁle obtained after use of an NRT
product and a commercially available CC. Part 2 investigated the
plasma nicotine PK proﬁle following use of the EVP with unﬂav-
oured e-liquids containing increasing levels of nicotine (0%, 0.4%,
0.9% and 2.0%). Safety parameters, smoking urges and withdrawal
symptoms were investigated in both study parts, and are published
elsewhere (Walele et al., 2015).
2. Materials and methods
2.1. Study design
This study was performed at a single clinical site (Simbec
Research Ltd, Wales) in a conﬁnement setting. A total of 24 healthy
male subjects, recruited in the UK, participated in the study: 12
assigned to Part 1 and 12 to Part 2. Both study parts were designed
as a randomised, controlled, four-way crossover trial. Part 1 was
performed open-label and Part 2 was blinded. Following overnight
abstinence from smoking or using EVPs, subjects used each
different product for one daily use session.
The study was approved by the South East Wales Research
Ethics Committees on 31 October 2013, and is registered at the US
National Institutes of Health (ClinicalTrials.gov) #NCT02032212. All
procedures were performed in accordance with the International
Conference on Harmonisation (ICH) Harmonised Tripartite Guide-
line for Good Clinical Practice (GCP). The MHRA-UK has granted
Clinical Trials Authorisation (CTA) for the use of the NRT product in
this study.
All subjects signed an informed consent form prior to any study
procedures being performed.
2.2. Study population
In order to be eligible, subjects had to be 21e65 years old, have a
body mass index (BMI) in the range of 18e35 kg/m2 and a self-
reported cigarette consumption of 5e30 cigarettes per day for at
least one year. Subjects had to test positive for urinary cotinine
(NicAlert strip with a score of 3 and above was considered positive)and for exhaled carbon monoxide (CO; measured with a portable
Bedfont Micro þ Smokerlyser device, where a readout of over six
ppm was considered positive).
Exclusion criteria included: taking or receiving any form of NRT,
snuff or chewing tobacco, or any intention to use it during the
study; willingness to stop smoking or considering to stop smoking;
use of any kind of medication within 14 days of the screening visit;
clinically signiﬁcant illness such as bronchitis or a history of any
clinically signiﬁcant disorders likely to affect study results; history
of drug or alcohol abuse or lung function test results considered
unsuitable.
2.3. Products used in this study
The EVP consisted of a rechargeable battery, an atomiser and
capsules that contained different e-liquids (Fig. 1). The capsules
were replaceable and the battery and atomiser were reusable. The
base components of the e-liquids used are propylene glycol
(70e75% w/w), glycerol (18e20% w/w) and water (5% w/w). Two e-
liquids were used in Part 1 of the study, which differed solely in
their ﬂavour content: an unﬂavoured base e-liquid with 2.0%
nicotine (UF2.0%; 2.7 mg/capsule) and a ﬂavoured (menthol) e-
liquid with 2.0% nicotine (FL2.0%; 2.7 mg/capsule). In Part 2, four
unﬂavoured e-liquids were used, which differed in their nicotine
content: 0% nicotine (UF0%), 0.4% nicotine (UF0.4%; 0.4%; 0.54 mg/
capsule), 0.9% nicotine (UF0.9%; 1.22 mg/capsule) and UF2.0%. The
EVP with UF2.0%, FL2.0% and UF0.4% delivers mean amounts of
0.013, 0.007 and 0.002 mg nicotine per puff, respectively (internal
data, generated under Health Canada Intense smoking regime).
Nicotine delivery with UF0.9% was not measured.
In Part 1 of the study, the NRT Nicorette Inhalator (15 mg
nicotine, manufacturer Johnson & Johnson; coded NIC15) was used
as a comparator product and the JPS Silver King Size CC (0.6 mg
nicotine; manufacturer Imperial Tobacco Group) was used as a
control.
2.4. Study interventions and schedule
Subjects visited the study site for a screening visit within 21
days of baseline (Day -2), where they were checked for eligibility
and were asked to sign a written informed consent form. De-
mographic data and smoking history were recorded using internal
questionnaires and the Fagerstr€om Test for Nicotine Dependence
(FTND) (Heatherton et al., 1991). At this stage, subjects were
assigned to Part 1 or Part 2 of the study, depending on their
availability. Once enrolled, the subjects were admitted to the study
site on the morning of Day -2 (baseline) for re-conﬁrmation of
eligibility, and were given training on how to use the EVP or NIC15.
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EVP, NRT or CC other than that assigned as part of the study design
and were not allowed to consume alcohol. On Day -1, the twelve
subjects in each study part were randomly assigned to one of four
pre-deﬁned sequences of product use, in a 3:3:3:3 ratio (random-
isation was performed using PROC PLAN procedures of SAS®
version 9.4). Subjects remained in the clinic until the end of the
study period, on the morning of Day 5.
On study Days 1, 2, 3, and 4, after overnight smoking abstinence,
subjects used the allocated product for four product administra-
tions at one-hour intervals (0 h, 1 h, 2 h and 3 h). Each adminis-
tration consisted of 10 inhalations at 30 s intervals. Each inhalation
was monitored, and subjects were instructed to take 4-s puffs for
the EVP and NIC15, and 2-s puffs for the CC (an electronic tablet was
used instructing subjects when to inhale and exhale). This regimen
was chosen based on published data indicating that experienced
EVP users take longer puffs than CC smokers (Farsalinos et al.,
2013b). PK blood samples (4.5 mL, from forearm vein, in lithium
heparin) for plasma nicotine were taken 1min before (1 min) and
1 min after (þ1 min) the ﬁrst, second and third product adminis-
trations, and 1 min before and at þ1, 2, 3, 4, 5, 6, 7, 8, 10, 13, 15, 30,
45 and 60min and atþ2, 4, 6, 8,12 and 21 h after the fourth product
administration.
On Day 5, subjects were provided full verbal smoking cessation
advice by the investigator and were discharged from the clinic after
all study assessments were performed.
2.5. Study outcome measures
For both study parts, the primary outcomes were Cmax
(maximum plasma concentration) and AUCt (area under the curve
from 0 to 21 h) after the 4th hourly administration, and the sec-
ondary outcomes were t1/2 (terminal half-life) and tmax (time to
Cmax) after 4th hourly administration.
2.6. Bioanalytical methods
Each human plasma sample (stored at 20 C) was thawed and
extracted with a solution of acetonitrile, ethanol, water, propane-2-
ol, ammonium acetate and formic acid containing the internal
standard nicotine-d4 (0.1 ng/mL) using a solid phase extraction
method (Waters Oasis HLB, 30 mg, 96 Well melution plate). Quan-
titative analysis of nicotine concentrations was performed using
liquid chromatography with tandem mass spectrometry detection
(Applied Biosystems MDS Sciex API 4000 triple quadrupole atmo-
spheric pressure ionisation) using the instrument in turbo ionspray,
positive ion Multiple Reaction Monitoring (MRM) mode. Chroma-
tography was performed on a Betasil silica-100 column. The in-
strument was calibrated for nicotine concentrations ranging from
0.5 ng/mL to 50 ng/mL. Themethodwas fully validated internally to
the standards required for submission of resulting data to regula-
tory authorities worldwide. The lower limit of quantiﬁcation
(LLOQ)was 0.5 ng/mL. Carboxyhaemoglobin (COHb) inwhole blood
samples was assessed with the Roche Cobas B221 Blood Gas Ana-
lyser System using a spectrophotometric method (Roche, 2009).
2.7. Statistical methods
2.7.1. Sample size
The sample size was selected based on similar PK studies for
similar products (Bullen et al., 2010; Dawkins and Corcoran, 2013;
Farsalinos et al., 2014b) and on guidance given by competent au-
thorities (EMA, 2010; HC, 2012). Twelve subjects per study part
were considered sufﬁcient in the crossover design as it is ensured
that all subjects used each of the four different products.2.7.2. PK parameters
For each study part, the plasma PK parameters for nicotine were
derived using non-compartmental methods from the individual
concentration-time data analysed with WinNonlin Phoenix 6.4. In
Part 1, CC and UF2.0% were used as reference products. AUCt and
Cmax values were logarithmically transformed (natural logarithm)
and then subjected to an analysis of variance (ANOVA) including
ﬁxed effects for sequence, day and product and a random effect for
subject. The least square means of the product differences and 90%
conﬁdence intervals (CIs) to the reference product were trans-
formed to the original scale in order to obtain the test/reference
geometric mean ratios (GMR). The statistical analysis was per-
formed only on the primary outcome measures Cmax and AUCt in
order to avoid an effect of multiple comparisons. In Part 2, dose
proportionality was assessed (excluding UF0%) by performing a
regression analysis of the log-transformed Cmax and AUCt values
versus the log-transformed dose with a ﬁxed effect for dose and a
random effect for subject. Slope estimates and associated 95% CIs
were calculated. All analyses were performed using SAS® version
9.1.3.
3. Results
3.1. Subjects' characteristics
Subjects were screened from January 2014 to March 2014. All 24
subjects enrolled for both study parts completed the study ac-
cording to the protocol. There were no withdrawals.
3.1.1. Part 1
The mean age of subjects was 31.1 years and the mean BMI was
25.0 kg/m2. The mean FTND score was 4.3, indicating moderate
nicotine dependence according to the FTND scale. Subjects smoked
between 5 and 30 cigarettes per day (self-reported), for 6e20 years.
At baseline (Day -2), urine cotinine levels were positive for all
subjects, with NicAlert scores ranging from 4 to 6. Blood COHb
levels ranged from 4.9 to 10.7% saturated haemoglobin and mean
exhaled CO levels were at 22.9 (±9.3) ppm. Subjects were thus
conﬁrmed smokers.
3.1.2. Part 2
The mean age of subjects was 37.4 years and the mean BMI was
26.1 kg/m2. The mean FTND score was 3.6, which indicated mod-
erate nicotine dependence according to that scale. Subjects smoked
between 5 and 30 cigarettes per day (self-reported). Themajority of
subjects had smoked for 6e20 years; one subject had smoked for
less than 6 years and ﬁve for over 20 years. Urine cotinine levels at
baseline were positive for smoking for all subjects, with NicAlert
scores ranging from 4 to 6. Blood COHb levels ranged from 4.1 to
10.5% saturated haemoglobin and mean exhaled CO levels were at
20.1 (±12.4) ppm. Subjects were thus conﬁrmed smokers.
3.2. Pharmacokinetics
3.2.1. Part 1
Fig. 2 shows the mean plasma concentration-time curves for
nicotine starting one minute prior to the ﬁrst product administra-
tion (181 min time-point) and up to 240 min after the 4th
administration (the 0 time point represents the 4th
administration).
Fig. 3 shows a close-up view of the curves for both EVPs and
NIC15, from the zero time point up to 45 min.
The plasma PK parameters (means or medians) Cmax, AUCt, tmax
and t1/2 obtained for nicotine after the 4th hourly administration
are summarised for each product in Table 1, and a summary of the
Fig. 2. Mean (±SEM) plasma nicotine concentration-time curves, shown for up to
240 min after the 4th product administration. Twelve subjects received each product
in a crossover design. UF2.0%, unﬂavoured base e-liquid at 2.0% nicotine; FL2.0%,
ﬂavoured base e-liquid at 2.0% nicotine; NIC15, Nicorette Inhalator 15 mg nicotine; and
CC, JPS 0.6 mg conventional cigarette; SEM, standard error of the mean.
Fig. 3. Mean (±SEM) plasma nicotine concentration-time curves, shown for EVP
products and NIC15 from zero up to 45 min after the 4th product administration.
Twelve subjects received each product in a crossover design. UF2.0%, unﬂavoured base
e-liquid at 2.0% nicotine; FL2.0%, ﬂavoured base e-liquid at 2.0% nicotine; NIC15, Nic-
orette Inhalator 15 mg nicotine; SEM, standard error of the mean.
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Mean Cmax and AUCt were statistically signiﬁcantly higher for CC
than for all other products. Cmax and AUCt for CC were 21.2 ng/mL
and 2247.0 min*ng/mL, respectively. Mean Cmax and AUCt for
UF2.0%were statistically signiﬁcantly higher than Cmax and AUCt for
FL2.0% (Table 2). Mean Cmax and AUCt for UF2% were 3.6 ng/mL andTable 1
Summary of nicotine PK parameters for each product for Part 1 and Part 2.
Product Cmax (ng/mL) AUCt (min*ng/m
Geometric mean (CV%) Geometric mean
Part 1
UF2.0% 3.6c (33.9) 425.3c (34.3)
FL2.0% 2.5b,c (41.6) 277.2b,c (48.2)
NIC15 2.5b,c (45.2) 320.6c (47.6)
CC 21.2b (43.1) 2247.0b (28.6)
Part 2
UF0% 0.6 (346.4) 83.9 (n/a)a
UF0.4% 1.0 (41) 57.7 (86.3)
UF0.9% 1.9 (32.8) 240.3 (82.8)
UF2.0% 3.6 (20.9) 451.4 (58.4)
Abbreviations: Cmax, maximumplasma concentration; AUCt, area under the curve from 0 t
n/a, not applicable; CV, coefﬁcient of variation; NC, not possible to calculate.
a Value based on n ¼ 1. All other values based on n ¼ 9e12.
b Statistically signiﬁcantly different from UF2.0% based on 90% CIs (Table 2).
c Statistically signiﬁcantly different from CC based on 90% CIs (Table 2).425.3 min*ng/mL, respectively and for FL2.0%, 2.50 ng/mL and
277.2 min*ng/mL. For NIC15, the Cmax and AUCt was 2.50 ng/mL and
320.56 min*ng/mL, however there was no statistically signiﬁcant
difference for AUCt between NIC15 and UF2.0%.
The shortest median tmax was observed for the CC (3.0 min),
indicating that the rate of nicotine absorptionwas fastest for the CC.
The median tmax values were similar for UF2.0% (9.0 min), FL2.0%
(10.0 min) and NIC15 (13 min). The median t1/2 values were similar
for the CC (125.6 min), UF2.0% (122.8 min), FL2.0% (111.4 min) and
NIC15 (124.2 min), suggesting that the elimination rate of nicotine
was comparable for the four product types.
3.2.2. Part 2
Fig. 4 shows the mean plasma concentration-time curves for
nicotine, starting one minute prior to the ﬁrst product adminis-
tration and up to 240 min after the 4th administration. The plasma
nicotine PK parameters Cmax, AUCt, tmax and t1/2 following the 4th
administration are summarised in Table 1 for each product.
The highest Cmax and AUCt values were observed for UF2.0%
(3.6 ng/mL and 451.4 min*ng/mL), followed by UF0.9% (1.9 ng/mL
and 240.3 min*ng/mL), UF0.4% (1.0 ng/mL and 57.7 min*ng/mL) and
UF0% (0.6 ng/mL and 83.9 min*ng/mL). Cmax and AUCt values for
UF0% were not zero since one subject, who was a heavy smoker
(21e30 cigarettes per day) and had residual nicotine levels in blood
during the study. Nicotine levels in bloodwere observed to increase
with successively higher nicotine concentrations in the EVP e-liq-
uids, even though the increase in Cmax and AUCt did not show full
dose proportionality (for Cmax, the slope estimate was 0.800 with a
95% CI of 0.710e0.889; for AUCt, the slope estimate was 1.281 with
a 95% CI of 1.005e1.557).
The median tmax was similar for UF0.4% (5.0 min), UF0.9%
(7.0min) and UF2.0% (7.0min). Although a tmax of 60.0 min for UF0%
was observed, this value was based on only one subject, who had
residual nicotine levels in blood. Themedian t1/2 for UF2.0%, UF0.9%
and UF0.4% were calculated at 125.1 min, 169.7 min and 57.6 min,
respectively.
4. Discussion
This study was conducted as part of the evaluation of an EVP
prototype.
In Part 1 of our study, the nicotine level in plasma samples
increased after each hourly administration of all products. The
maximum mean plasma nicotine level in subjects using EVPs was
3.6 ng/mL, which was reached in nine minutes. NIC15 produced a
maximum mean plasma nicotine level of 2.5 ng/mL, 13 min afterL) tmax (min) t1/2 (min)
(CV%) Median (range) Median (range)
9.0 (1.0e15.0) 122.8 (76.2e183.2)
10.0 (3.0e45.0) 111.4 (54.3e203.4)
13.0 (5.0e15.0) 124.2 (64.1e291.0)
3.0 (1.0e6.0) 125.6 (87.1e301.3)
60 (n/a)a NC
5.0 (1.0e60.0) 57.6 (16.5e389.7)
7.0 (1.0e15.0) 169.4 (70.1e372.5)
7.0 (3.0e30.0) 125.1 (55.0e242.5)
o 21 h after the 4th product administration; tmax, time to Cmax; t1/2, terminal half-life;
Table 2
Statistical analysis for the nicotine PK parameters Cmax and AUCt, for Part 1 of the study.
UF2.0% FL2.0% NIC15 CC
(N ¼ 12) (N ¼ 12) (N ¼ 12) (N ¼ 12)
Cmax (ng/mL)
Geometric LSMean 3.64 2.5 2.5 21.16
Geometric LSMean ratio (product/UF2.0%) (90% CI) n/a 0.69 (0.52e0.91) 0.69 (0.52e0.91) 5.81 (4.38e7.71)
Geometric LSMean ratio (product/CC) (90% CI) 0.17 (0.13e0.23) 0.12 (0.09e0.16) 0.12 (0.09e0.16) n/a
AUCt (min*ng/mL)
Geometric LSMean 425.33 277.16 320.56 2246.96
Geometric LSMean ratio (product/UF2.0%) (90% CI) n/a 0.65 (0.47e0.90) 0.75 (0.55e1.04) 5.28 (3.84e7.26)
Geometric LSMean ratio (product/CC) (90% CI) 0.19 (0.14e0.26) 0.12 (0.09e0.17) 0.14 (0.10e0.20) n/a
Twelve subjects received each product in a crossover design. The statistical parameters were obtained using amixed effects ANOVAwith ﬁxed effects of study period, sequence
and treatment and a random effect of subject (nested in sequence).
Abbreviations: Cmax, maximum plasma concentration; AUCt, area under the curve from 0 to 21 h after the 4th product administration. n/a, not applicable.
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nicotine plasma PK proﬁle obtained with the tested EVPs is very
similar to that obtained following the use of NIC15 (i.e. that the EVP
prototype is as effective as NIC15 in raising systemic nicotine
levels). Our results are in agreement with ﬁndings from other
studies conducted with CC smokers who used an EVP for the ﬁrst
time and whose blood nicotine levels stayed below 5 ng/mL (Bullen
et al., 2010; Hajek et al., 2014; Vansickel et al., 2010). In absolute
terms, nicotine exposures were substantially (8-fold) lower for the
EVP, regardless of the presence of ﬂavouring, than for the CC. All
four products had a similar t1/2, indicating that the type of product
used for nicotine administration does not inﬂuence the rate of
nicotine elimination.
As seen on Fig. 3, nicotine Cmax was higher for UF2.0% compared
with FL2.0%. Even if it was statistically signiﬁcant, that difference is
of a small magnitude when put in perspective with the Cmax value
obtained with CC. The effect of menthol on nicotine PK has also
been studied in smokers of CCs. The available evidence indicates
that in most smokers, menthol has no effect on nicotine absorption
(Benowitz et al., 2004;Wang et al., 2010;Werley et al., 2007). Use of
the ﬂavoured EVP resulted in tmax and t1/2 values similar to the
unﬂavoured product, indicating that the added ﬂavours had a
limited effect, if any, on nicotine absorption and elimination rates.
As EVP consumers report that having a choice of ﬂavours is
important in order to reduce or quit CC smoking (Farsalinos et al.,
2013a), any regulation limiting the use of ﬂavours could be
counter-productive and should be thoroughly evaluated on a case-
by-case basis. The comparability of the nicotine plasma PK proﬁle ofFig. 4. Mean (±SEM) plasma nicotine concentration-time curves, shown for up to
240 min after the 4th product administration. Twelve subjects received each product
in a crossover design. UF2.0%, unﬂavoured base liquid at 2.0% nicotine; UF0.9%,
unﬂavoured base liquid at 0.9% nicotine; UF0.4%, unﬂavoured base liquid at 0.4%
nicotine and UF0%, unﬂavoured base liquid at 0% nicotine; SEM, standard error of the
mean.EVPs tested in our study and NIC15 may suggest that they share at
least part of the nicotine absorption mechanisms, e.g. from the oral
mucosa and the pharynx. It has been reported (Spindle et al., 2015)
that experienced EVP users obtained nicotine exposures similar to
CC smokers immediately after use when using third-generation
products. This may be suggestive of the presence of pulmonary
absorption routes for nicotine following delivery by third-
generation devices, and investigations of the respective sites of
nicotine absorption for different generation EVPs and different
subjects therefore warrants further research.
In Part 2 of our study, the PK parameters found for UF2.0% were
very similar to those found in Part 1, even though in general, a
higher inter-subjects variability was observed in Part 2. This is an
indication that our results were reproducible, and that despite the
observed variability, the number of subjects was appropriate. Part 2
showed that increasing nicotine concentrations in the e-liquids
resulted in higher plasma nicotine levels, even though the increase
did not show direct dose proportionality (the mean Cmax was
1.0 ng/mL with UF0.4%, 1.9 ng/mL with UF0.9% and 3.6 ng/mL with
UF2.0%). In another study, a Cmax of 4.6 ng/mL was reached with an
EVP containing 2.4% nicotine in its e-liquid (Hajek et al., 2014). It
has also recently been shown that the yield of nicotine from an EVP
correlates with the nicotine content in the e-liquids used with the
device (Talih et al., 2015). Taken together, these results indicate that
there is a dose-relationship between plasma nicotine levels and the
nicotine concentration in e-liquids, even though strict dose pro-
portionality was not demonstrated in our study.
Under the revised European Tobacco Products Directive,
(Directive 2014/40/EU e effective May 2016), Article 20 prohibits
manufacturers fromplacing on themarket e-liquids whose nicotine
concentration exceeds 20mg/mL (2%w/v). If manufacturers wish to
exceed this level, they must have obtained a medical product li-
cense from the Member States competent authority (2014). The UK
MHRA have placed guidance on its website on the licensing pro-
cedure for EVPs as medical products (MHRA, 2015). The guidance
states that given the intended route of administration, an inhaled
nicotine product such as the Nicorette® Inhalator has been advised
as being a suitable reference product. It further states, in order for
conclusions regarding the safety and efﬁcacy of a product to be
reached, it is necessary to show where the product ‘sits’ in relation
to other nicotine containing products (NCPs) and cigarettes, in
terms of its nicotine PK proﬁle. In addition to nicotine, excipients
and ﬂavouring compounds, a number of toxicants such as carbonyls
have also been reported in EVP aerosols (Farsalinos et al., 2014a;
Goniewicz et al., 2013; Hutzler et al., 2014; Kosmider et al., 2014).
The levels of these toxicants delivered to the user depend upon the
volume of aerosol inhaled, and the design of the EVP. Product
design characteristics such as power output, along with user
T. Walele et al. / Regulatory Toxicology and Pharmacology 74 (2016) 187e192192behaviours have been shown to inﬂuence aerosol composition, and
therefore user exposures (Kosmider et al., 2014; Talih et al., 2015). A
framework that takes into account all these parameters for deﬁning
nicotine deliveries of EVPs need to be considered in the develop-
ment of future regulation.
The EVP prototype tested in this study, when used on a short-
term basis, resulted in comparable plasma nicotine PK proﬁles to
an MHRA approved NRT product. The present study demonstrates
that at the maximum e-liquid nicotine concentration of 2% as
prescribed by the EU Tobacco Product Directive, the EVP device
offered nicotine delivery that was comparable to the Nicorette®
inhalator, with the advantage of replicating certain ritualistic ele-
ments of smoking a CC. The EVP studied here thus offers an alter-
native to NRT products, providing it complies with the safety,
quality and efﬁcacy standards set by a medicinal regulator, e.g. the
UK MHRA.
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